TY - JOUR T1 - Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada JF - The Journal of Rheumatology JO - J Rheumatol SP - 1440 LP - 1447 DO - 10.3899/jrheum.171307 VL - 45 IS - 10 AU - Stephanie O. Keeling AU - Asvina Bissonauth AU - Sasha Bernatsky AU - Ben Vandermeer AU - Paul R. Fortin AU - Dafna D. Gladman AU - Christine Peschken AU - Murray B. Urowitz Y1 - 2018/10/01 UR - http://www.jrheum.org/content/45/10/1440.abstract N2 - Objective. To evaluate the diagnosis, monitoring, and treatment of systemic lupus erythematosus (SLE) in Canada.Methods. A 63-question electronic survey was developed with the Canadian Rheumatology Association and others. Descriptive analyses of responses were performed.Results. Survey respondents (n = 175) reported varying practices in the diagnosis, monitoring, and treatment of SLE. Performance of laboratory investigations for diagnosis and monitoring varied, with 78% of responders performing them at least every 6 months. Validated measures of SLE disease activity and damage were not commonly used. Most common first-line agents besides steroids for induction therapy for class III or IV lupus nephritis included intravenous cyclophosphamide and mycophenolate mofetil. Antimalarial use was common, with 96% of respondents using these in active skin disease. Over 60% of respondents indicated that 80–100% of their patients were taking antimalarials, while another 25% indicated they used these drugs in up to 80% of their patients. There were 71% of responders who reported completing frequent (6–12 mos) ophthalmology screening in patients taking antimalarials. Biologics were infrequently used. Responders were more likely to stop azathioprine and chloroquine than hydroxychloroquine in pregnant patients with SLE. Other aspects of routine care including vaccination and cardiovascular risk management varied considerably. The majority (80%) agreed that a dedicated multidisciplinary care team would improve SLE care.Conclusion. Considerable practice variation in SLE management was noted. This may help inform future recommendations for the diagnosis, monitoring, and treatment of SLE in Canada. ER -